Centiva Capital LP Purchases 12,125 Shares of Danaher Co. (NYSE:DHR)

Centiva Capital LP boosted its position in shares of Danaher Co. (NYSE:DHR) by 286.0% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 16,365 shares of the conglomerate’s stock after purchasing an additional 12,125 shares during the quarter. Centiva Capital LP’s holdings in Danaher were worth $4,550,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in DHR. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher during the second quarter worth approximately $25,000. nVerses Capital LLC acquired a new stake in Danaher during the 2nd quarter worth $25,000. Teachers Insurance & Annuity Association of America bought a new stake in shares of Danaher during the 3rd quarter valued at $39,000. MidAtlantic Capital Management Inc. acquired a new position in shares of Danaher in the 3rd quarter valued at $40,000. Finally, FSA Wealth Management LLC bought a new position in shares of Danaher in the 3rd quarter worth $50,000. 79.05% of the stock is currently owned by institutional investors and hedge funds.

Danaher Stock Down 0.3 %

Shares of Danaher stock opened at $239.00 on Monday. Danaher Co. has a 52-week low of $215.68 and a 52-week high of $281.70. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.01 and a current ratio of 1.37. The business’s 50 day simple moving average is $254.59 and its 200 day simple moving average is $259.41. The firm has a market cap of $172.62 billion, a PE ratio of 45.74, a P/E/G ratio of 4.41 and a beta of 0.85.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.57 by $0.14. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period last year, the company earned $2.02 earnings per share. The firm’s revenue was up 3.1% compared to the same quarter last year. On average, analysts predict that Danaher Co. will post 7.5 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were paid a dividend of $0.27 per share. The ex-dividend date was Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.45%. Danaher’s dividend payout ratio is 20.61%.

Analyst Upgrades and Downgrades

DHR has been the subject of a number of recent analyst reports. Stifel Nicolaus upped their price objective on Danaher from $250.00 to $265.00 and gave the company a “hold” rating in a report on Wednesday, October 23rd. StockNews.com raised Danaher from a “hold” rating to a “buy” rating in a research note on Wednesday, November 27th. Evercore ISI lifted their price objective on shares of Danaher from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Robert W. Baird decreased their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. Finally, Raymond James cut their target price on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a report on Wednesday, October 23rd. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. According to MarketBeat, Danaher presently has a consensus rating of “Moderate Buy” and a consensus target price of $287.16.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.